Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538471 · ClinicalTrials.gov registry record · Phase 2
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02538471 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 3 participants.
The verdict
NCT02538471, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Patients with metastatic breast cancer receiving at least one single agent chemotherapy and demonstrating stable disease or disease progression at two consecutive clinical/radiological assessments (at an interval of at least 2 weeks). Transforming growth factor-beta (TGFΒ) blockade will enhance response of irradiated tumors and improve the function of Dendritic and T cells. Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle). Radiation to a metastatic site will be delivered at a dose of 7.5 Gy, given consecutively on days 1-3-5.
Interventions
- RADIATION Radiation therapy
- DRUG Study Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2019-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02538471
The ClinicalTrials.gov registry entry for NCT02538471 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation therapy is the first listed.
NCT02538471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02538471 about?
NCT02538471 is a clinical study titled "LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer". Patients with metastatic breast cancer receiving at least one single agent chemotherapy and demonstrating stable disease or disease progression at two consecutive clinical/radiological assessments (at an interval of at least 2 weeks). Transforming growth factor-beta (TGFΒ) blockade will enhance res...
What is the current status of trial NCT02538471?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-08-10. Estimated completion is 2019-02-20.
What interventions are being tested in trial NCT02538471?
The interventions under investigation include: Radiation therapy (RADIATION), Study Drug (DRUG).
Who is sponsoring clinical trial NCT02538471?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.